Stock analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Rating) in a report released on Friday. The firm set a "sell" rating on the stock.
DBV Technologies Price Performance
DBVT stock opened at $1.41 on Friday. The stock has a market capitalization of $265.15 million, a P/E ratio of -2.56 and a beta of 1.39. The business has a 50-day moving average of $1.48 and a 200-day moving average of $1.98. DBV Technologies has a fifty-two week low of $1.15 and a fifty-two week high of $3.43.
Get DBV Technologies alerts:Hedge Funds Weigh In On DBV Technologies
Large investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of DBV Technologies by 16.5% in the 1st quarter. BlackRock Inc. now owns 687,341 shares of the company's stock valued at $1,093,000 after purchasing an additional 97,412 shares during the last quarter. ExodusPoint Capital Management LP bought a new position in shares of DBV Technologies in the 2nd quarter worth about $352,000. BNP Paribas Arbitrage SNC raised its position in shares of DBV Technologies by 203.3% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 57,899 shares of the company's stock worth $102,000 after acquiring an additional 38,812 shares in the last quarter. Envestnet Asset Management Inc. bought a new position in shares of DBV Technologies in the 3rd quarter worth about $67,000. Finally, Two Sigma Investments LP increased its position in DBV Technologies by 80.9% in the 3rd quarter. Two Sigma Investments LP now owns 35,920 shares of the company's stock valued at $64,000 after buying an additional 16,066 shares in the last quarter. Institutional investors own 27.55% of the company's stock.
About DBV Technologies
(Get Rating)DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
Recommended Stories
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.